PIPELINE

Acineto Vax (VXD-001)

Active principle: Inactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine

Stage: Preclinical development

Indication: Raise active immunity against 100% of circulating strains of Acinetobacter baumannii, in the population in hospitals or the community at risk of developing infections by A. baumannii.

Highlights: Multi-antigen presentation leads to potent humoral and cell-mediated immunity, 100% protective in animal models. Two well conserved immunodominant Outer-Membrane Proteins (OMPs) identified as the major contributors to protective immunity. The absence of LPS and conservation of the immunodominant OMPs lead to vaccine universality (high strain coverage). Manufacturing process developed. The drug substance does not need purification, since it is based on whole cells. Editing VXD-001 in order to make multi-valent vaccine candidates has become Vaxdyn’s validated technological platform.

KapaVax (VXD-005)

Active principle: Inactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Pseudomonas aeruginosa and Klebsiella pneumoniae.

Stage: Preclinical development

Indication: Raise active immunity against 100% of circulating strains of each Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae in the population in hospitals or the community at risk of developing infections by these bacteria.

Highlights: First multivalent vaccine candidate of Vaxdyn’s technological platform. First proof of principle in humans expected in 2023. Product powered by the global accelerator CARB-X.

VAXDYN IS EXPANDING THE PIPELINE BY DELIVERING EDITED VXD-001 CELLS FOR DISPLAYING HETEROLOGOUS ANTIGENS FROM OTHER ANTIBIOTIC-RESISTANT BACTERIA